The United Kingdom’s National Health Service (NHS) recently announced that in its last fiscal year, it had saved $419 million in switching to biosimilar and generic versions of ten expensive drugs. These savings exceeded the $324 million in savings the NHS had forecasted. According to the announcement, most of the savings came from switching to biosimilars:
- infliximab ($128 million)
- imatinib ($85 million)
- etanercept ($78 million)
- rituximab ($65 million)
The NHS further noted that the drug it spends the most money on is adalimumab, which the NHS expects to be available as a biosimilar after October 2018. The NHS indicated that it expects to have even more savings this year from switching to biosimilars and generics.
The post NHS Announces Unexpected Increase in Savings from Switching to Biosimilars appeared first on Big Molecule Watch.